foto

MD PhD M. Lowenberg

Position
Medical Specialist
Main activities
Patient care, Research
Specialisation
Gastroenterology and hepatology
Focus of research

Inflammatory bowel diseases; T lymphocytes; mucosal immunity; signal transduction;  small molecules; glucocorticoids

Key publications
  • Löwenberg Mark, Tuynman Jurriaan, Bilderbeek Joyce, Gaber Timo, Buttgereit Frank, van Deventer Sander, Peppelenbosch Maikel, Hommes Daniel Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn Blood 2005;106 (5):1703-1710 [PubMed]
  • Löwenberg Mark, Verhaar Auke P., Bilderbeek Joyce, Marle Jan van, Buttgereit Frank, Peppelenbosch Maikel P., van Deventer Sander J., Hommes Daniel W. Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN EMBO reports 2006;7 (10):1023-1029 [PubMed]
  • de Jonge Wouter J., The Frans O., Löwenberg Mark, Boeckxstaens Guy E. P38 MAPK Inhibitor Semapimod Reduces Postoperative Ileus Via Peripheral and Central Mechanisms Gastroenterology 2009;136 (5):1841-1842 [PubMed]
  • Löwenberg Mark, Verhaar Auke, van den Blink Bernt, ten Kate Fibo, van Deventer Sander, Peppelenbosch Maikel, Hommes Daniel Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease Journal of immunology (Baltimore, Md. 2005;175 (4):2293-2300 [PubMed]
  • Löwenberg Mark, Tuynman Jurriaan, Scheffer Meike, Verhaar Auke, Vermeulen Louis, van Deventer Sander, Hommes Daniel, Peppelenbosch Maikel Kinome analysis reveals nongenomic glucocorticoid receptor-dependent inhibition of insulin signaling Endocrinology 2006;147 (7):3555-3562 [PubMed]
All Publications
Curriculum Vitae

Date of birth: January 04, 1977. Place of birth: Rotterdam
Degrees: MD, PhD
 

Education:
2003-2006: PhD, Dept. of Gastroenterology and Hepatology, AMC, Amsterdam. Thesis title: Therapeutic agents and signal transduction in inflammatory bowel diseases. Supervisors: prof. dr. S.J. van Deventer, prof. dr. M.P. Peppelenbosch, prof. dr. D.W. Hommes.
1996-2003: Medical Doctor, University of Amsterdam (Master of Science: March 2003).
1995-1996: Propaedeutics exam Faculty of Medicine, Erasmus University Rotterdam.
1989-1995: High School, Montessori Lyceum Rotterdam.

Postdoctoral training:
2008-2012: Clinical fellow, Dept. of Gastroenterology and Hepatology, AMC, Amsterdam.
2006-2008: Resident, Dept. of Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam.

Professional societies:
2007-present: Member of the Emerging Leaders Program in Gastroenterology.

Scientific Research:
2000 September-December: Research internship. Biotechnology company Crucell, Leiden, the Netherlands. Testing the stability of viral vectors for gene therapy.
2000 February-July: Research internship. Harvard Medical School, Dana Farber Cancer Institute, Boston, USA. Functional implications of FKBP-51 expression in prostate cancer.

Awards:
2007 AstraZeneca Gastrointestinal Research Award.

Publications:
1) Therapeutic modulation of signal transduction pathways. Löwenberg M, Peppelenbosch M, Hommes D. Inflamm Bowel Dis. 2004;10 Suppl.1:S52-7.
2) Glucocorticoid action and molecular mechanisms of steroid resistance: from molecules to patients. Löwenberg M, Hommes D. BTi Journal. 2004; 16(4):6-9.
3) Androgen mediated regulation and functional implications of FKBP-51 expression in prostate cancer. Febbo P, Löwenberg M, Thorner A, Brown M, Loda M, Golub T. J Urology. 2005;173(5):1772-7.
4) Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn. Löwenberg M, Tuynman J, Bilderbeek J, Gaber T, Buttgereit F, van Deventer S, Peppelenbosch M, Hommes D. Blood. 2005;106(5):1703-10.
5) Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease. Löwenberg M, Verhaar A, van den Blink B, Ten Kate F, van Deventer S, Peppelenbosch M, Hommes D.
J Immunol. 2005;175(4):2293-300.
6) Kinome analysis reveals nongenomic glucocorticoid receptor dependent inhibition of insulin signaling. Löwenberg M, Tuynman J, Verhaar A, Scheffer M, Vermeulen L, van Deventer S, Hommes D, Peppelenbosch M. Endocrinology. 2006;147(7):3555-62.
7) A role for STAT5 in steroid resistant ulcerative colitis? Löwenberg M, Scheffer M, Verhaar A, Peppelenbosch M, Hommes D. Inflamm Bowel Dis. 2006;12(7):665.
8) Glucocorticoids cause rapid dissociation of a T cell receptor-associated protein complex containing Lck and Fyn. Löwenberg M, Verhaar A, Bilderbeek J, van Marle J, Buttgereit F, Peppelenbosch M, van Deventer S, Hommes S. EMBO Rep. 2006;7(10):1023-9.
9) Biological therapy in the management of recent-onset Crohn's disease: why, when and how? Löwenberg M, Peppelenbosch M, Hommes D. Drugs. 2006;66(11):1431-9.
10) Glucocorticoid signaling: a nongenomic mechanism for T-cell immuno-suppression. Löwenberg M, Verhaar A, Van den Brink G, Hommes D. Trends Mol Med. 2007;13(4):158-63.
11) Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Stahn C, Löwenberg M, Hommes D, Buttgereit F. Mol Cell Endocrinol. 2007;15;275(1-2):71-8.
12) Proximal signaling molecules as potential targets for anti-inflammatory therapy. Löwenberg M. Curr Opin Drug Discov Devel. 2007;10(5):560-4.
13) Glucocorticoids, from mechanisms to applications. Löwenberg M, Stahn C, Hommes D, Buttgereit F. Steroids 2008; 73(9-10):1025-9.
14) P38 MAPK inhibitor semapimod reduces post-operative ileus via peripheral and central mechanisms. de Jonge WJ, The FO, Löwenberg M, Boeckxstaens GE. Gastroenterology. 2009;136(5):1841-2.
15) Comparison of peptide array substrate phosphorylation of c-Raf and mitogen activated protein kinase kinase kinase 8. Parikh K, Diks SH, Tuynman JH, Verhaar A, Löwenberg M, Hommes DW, Joore J, Pandey A, Peppelenbosch MP. PLoS One. 2009 Jul 30;4(7):e6440.
16) Third generation kinomic profiling identifies Met dependent regulation of the Wnt pathway in APC mutation harboring colorectal cancer. Tuynman J, Löwenberg M, Vermeulen L, Verdurmen H, Diks S, Zwinderman A, Pandey A, Richel1 D, Peppelenbosch M. Manuscript in preparation.

Teaching skills:
2005, 2006 Training course for nurses dept. of internal medicine AMC. Topic: Current and future therapies for inflammatory bowel diseases.


 

Research programmes

(Medewerkers buiten research programmes van afdeling Maag-Darm-Leverziekten)

Prof. PhD G.R.A.M. D'Haens (CHRONIC INFLAMMATORY BOWEL DISEASES)

Prof. PhD R.A.A. Mathot (Population pharmacokinetic-pharmacodynamic (PK-PD) research)

Current research funding
  • AbbVie B.V.
  • Atlantic Healthcare plc/Atlantic Pharmaceuticals Ltd
  • Celgene Int. Sarl c/o PPD Investigator Services, LLC
  • Celgene International Il Sаrl
  • Celgene International Sarl
  • Covance International Holdings B.V.
  • Covidien AG
  • Dr. Falk Pharma Benelux B.V.
  • Eli Lilly Cork Limited
  • GETAID
  • Gilead Sciences, Inc.
  • GlaxoSmithKline BV
  • IQVIA RDS Netherlands B.V.
  • Janssen Cilag B.V.
  • Robarts Clinical Trials B.V,
  • UMC St. Radboud
  • ZonMw